Frățilă, G.; Sorohan, B.M.; Achim, C.; Andronesi, A.; Obrișcă, B.; Lupușoru, G.; Zilișteanu, D.; Jurubiță, R.; Bobeică, R.; Bălănică, S.;
et al. Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome. J. Clin. Med. 2023, 12, 6895.
https://doi.org/10.3390/jcm12216895
AMA Style
Frățilă G, Sorohan BM, Achim C, Andronesi A, Obrișcă B, Lupușoru G, Zilișteanu D, Jurubiță R, Bobeică R, Bălănică S,
et al. Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome. Journal of Clinical Medicine. 2023; 12(21):6895.
https://doi.org/10.3390/jcm12216895
Chicago/Turabian Style
Frățilă, Georgiana, Bogdan Marian Sorohan, Camelia Achim, Andreea Andronesi, Bogdan Obrișcă, Gabriela Lupușoru, Diana Zilișteanu, Roxana Jurubiță, Raluca Bobeică, Sonia Bălănică,
and et al. 2023. "Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome" Journal of Clinical Medicine 12, no. 21: 6895.
https://doi.org/10.3390/jcm12216895
APA Style
Frățilă, G., Sorohan, B. M., Achim, C., Andronesi, A., Obrișcă, B., Lupușoru, G., Zilișteanu, D., Jurubiță, R., Bobeică, R., Bălănică, S., Micu, G., Mocanu, V., & Ismail, G.
(2023). Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome. Journal of Clinical Medicine, 12(21), 6895.
https://doi.org/10.3390/jcm12216895